Advanced

The neurobiology of cell transplantation in Parkinson's disease

Brundin, Patrik LU and Hagell, Peter LU (2001) In Clinical Neuroscience Research 1(6). p.507-520
Abstract
Over the past decade, neural grafting has emerged as a new treatment option for Parkinson's disease. When performed successfully, grafts of human embryonic neural tissue can give rise to major symptomatic relief in patients, However, a recent report on a double-blind placebo control study, which received worldwide attention, described less pronounced beneficial effects of the grafts, and found them to be significant only in patients younger than 60 years of age. Moreover, a subgroup of patients developed disabling dyskinesias as a result of the surgery. These findings, and great logistical problems in coordinating the harvesting of sufficient amounts of suitable human embryonic donor tissue with the transplantation surgery, have led the... (More)
Over the past decade, neural grafting has emerged as a new treatment option for Parkinson's disease. When performed successfully, grafts of human embryonic neural tissue can give rise to major symptomatic relief in patients, However, a recent report on a double-blind placebo control study, which received worldwide attention, described less pronounced beneficial effects of the grafts, and found them to be significant only in patients younger than 60 years of age. Moreover, a subgroup of patients developed disabling dyskinesias as a result of the surgery. These findings, and great logistical problems in coordinating the harvesting of sufficient amounts of suitable human embryonic donor tissue with the transplantation surgery, have led the scientific community to question whether cell transplantation really has a future as a therapy for Parkinson's disease. In this review, we argue that the future of neural transplantation for Parkinson's disease is still bright. We relate clinical findings to observations made in experimental animals grafted with embryonic neural tissue and seek explanations for the variability in outcome seen in the clinical trials. We also briefly discuss alternative sources of donor tissue that may be applied in future clinical trials, and mention what features of cells may be crucial for them to be suitable as donor tissue for transplantation in Parkinson's disease. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Parkinson's disease, Neural transplantation, Human, Rat, Dopamine, Immunosuppression, Stem cells, Xenografts
in
Clinical Neuroscience Research
volume
1
issue
6
pages
507 - 520
publisher
Elsevier
external identifiers
  • wos:000174288900011
  • scopus:0001552886
ISSN
1873-779X
DOI
10.1016/S1566-2772(01)00028-7
language
English
LU publication?
yes
id
30e47192-4084-4341-b707-e3b1e00b035f (old id 1118468)
date added to LUP
2008-06-25 14:14:55
date last changed
2018-05-29 10:35:38
@article{30e47192-4084-4341-b707-e3b1e00b035f,
  abstract     = {Over the past decade, neural grafting has emerged as a new treatment option for Parkinson's disease. When performed successfully, grafts of human embryonic neural tissue can give rise to major symptomatic relief in patients, However, a recent report on a double-blind placebo control study, which received worldwide attention, described less pronounced beneficial effects of the grafts, and found them to be significant only in patients younger than 60 years of age. Moreover, a subgroup of patients developed disabling dyskinesias as a result of the surgery. These findings, and great logistical problems in coordinating the harvesting of sufficient amounts of suitable human embryonic donor tissue with the transplantation surgery, have led the scientific community to question whether cell transplantation really has a future as a therapy for Parkinson's disease. In this review, we argue that the future of neural transplantation for Parkinson's disease is still bright. We relate clinical findings to observations made in experimental animals grafted with embryonic neural tissue and seek explanations for the variability in outcome seen in the clinical trials. We also briefly discuss alternative sources of donor tissue that may be applied in future clinical trials, and mention what features of cells may be crucial for them to be suitable as donor tissue for transplantation in Parkinson's disease.},
  author       = {Brundin, Patrik and Hagell, Peter},
  issn         = {1873-779X},
  keyword      = {Parkinson's disease,Neural transplantation,Human,Rat,Dopamine,Immunosuppression,Stem cells,Xenografts},
  language     = {eng},
  number       = {6},
  pages        = {507--520},
  publisher    = {Elsevier},
  series       = {Clinical Neuroscience Research},
  title        = {The neurobiology of cell transplantation in Parkinson's disease},
  url          = {http://dx.doi.org/10.1016/S1566-2772(01)00028-7},
  volume       = {1},
  year         = {2001},
}